Australia Vaccine Market 2026 | Projected to Reach USD 2,785.10 Million by 2034

Market Overview

The Australia vaccine market was valued at USD 1,305.43 Million in 2025 and is projected to reach USD 2,785.10 Million by 2034. It is expected to grow at a compound annual growth rate of 8.78% over the forecast period from 2026 to 2034. The market expansion is fueled by Australia's National Immunisation Program, rising infectious diseases, technological vaccine innovations, and considerable government investments in manufacturing and pandemic preparedness. This growth positions Australia as a regional vaccine manufacturing and distribution leader.

Request a Sample Report with Latest 2026 Data & Forecasts: https://www.imarcgroup.com/australia-vaccine-market/requestsample

How AI is Reshaping the Future of Australia Vaccine Market:

• AI-driven data analytics optimize vaccine supply chains, reducing disruptions and enhancing distribution efficiency, supporting Australia's increased domestic manufacturing capacity producing over 100 million doses annually.

• AI assists in accelerating vaccine development processes through machine learning models tailored for novel vaccine formulations, including maternal RSV vaccines now funded under national programs.

• Intelligent automation enables enhanced immunization workforce scalability by facilitating pharmacist and intern pharmacist vaccination authorizations, expanding vaccine accessibility at community pharmacies.

• AI-powered predictive models support government health initiatives by monitoring infectious disease trends, such as managing Australia's record respiratory illness incidence and influenza alerts.

• AI tools improve public trust and vaccine uptake by combating misinformation via targeted educational campaigns aligned with the National Immunization Strategy 2025-2030.

• AI enhances patient management in hospitals by integrating immunization schedules with electronic health records, ensuring vulnerable populations receive timely vaccines like the new Prevenar 20 pneumococcal vaccine.

Market Growth Factors

The Australia vaccine market growth is primarily driven by the rising infectious disease burden which has significantly increased vaccine demand. The 2024 influenza season registered 349,728 influenza alerts-the worst since 2019-heightening vaccine awareness among healthcare providers, policymakers, and the public. This awareness has propelled expanded vaccination programs and investments in immunization infrastructure. Additionally, resurgence of diseases like measles, particularly from Asia-Pacific, has necessitated vigilant catch-up vaccination efforts, reinforcing immunization coverage across vulnerable populations.

Strategic government investments in domestic vaccine manufacturing have bolstered market growth by enhancing sovereign capabilities and pandemic preparedness. Notable advancements include Moderna's facility in Victoria producing up to 100 million vaccine doses annually and CSL Seqirus's cell-based influenza vaccine plant in Tullamarine, the only such facility in the Southern Hemisphere. These establishments mitigate international supply dependencies, enabling rapid responses to health emergencies and strengthening Australia's vaccine supply chains.

Continuous expansion and diversification of the National Immunization Program play a critical role in market sustainability. The inclusion of the National RSV Mother and Infant Protection Program, offering free maternal RSV vaccination and infant monoclonal antibody prophylaxis, coupled with the switch from Prevenar 13 to Prevenar 20 extending pneumococcal coverage, illustrate program enhancement. Furthermore, the commencement of community pharmacy vaccination services under the NIPVIP Program since January 2024 has improved vaccine accessibility for individuals aged five years and above, promoting equitable and widespread immunization coverage.

Browse the Full Report with TOC & List of Figures: https://www.imarcgroup.com/australia-vaccine-market

Market Segmentation

Technology Insights:

• Conjugate Vaccines

• Inactivated and Subunit Vaccines

• Live Attenuated Vaccines

• Recombinant Vaccines

• Toxoid Vaccines

• Others

Patient Type Insights:

• Paediatric

• Adult

Indication Insights:

• Bacterial Diseases

o Meningococcal Disease

o Pneumococcal Disease

o Diphtheria/Tetanus/Pertussis (DPT)

o Tuberculosis

o Haemophilus Influenzae (Hib)

o Typhoid

o Others

• Viral Diseases

o Hepatitis

o Influenza

o Human Papillomavirus (HPV)

o Measles/Mumps/Rubella (MMR)

o Rotavirus

o Herpes Zoster

o Varicella

o Japanese Encephalitis

o Rubella

o Polio

o Rabies

o Dengue

o Others

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration

• Oral Administration

• Others

Product Type Insights:

• Multivalent Vaccine

• Monovalent Vaccine

Treatment Type Insights:

• Preventive Vaccine

• Therapeutic Vaccine

Distribution Channel Insights:

• Hospital Pharmacies

• Retail Pharmacies

• Institutional Sales

• Others

End User Insights:

• Hospitals

• Clinics

• Vaccination Centers

• Academic and Research Institutes

• Others

Regional Insights:

• Australia Capital Territory & New South Wales

• Victoria and Tasmania

• Queensland

• Northern Territory & Southern Australia

• Western Australia

Recent Development & News

• February 2025: The National RSV Mother and Infant Protection Program began, offering pregnant women free access to the Abrysvo vaccine under the National Immunisation Program. Early data from Western Australia reports nirsevimab effectiveness of 88.2% against RSV-related hospitalization, reducing hospital admissions by 57% compared to forecasts.

• January 2024: Launch of the National Immunisation Program Vaccinations in Pharmacy (NIPVIP) Program enhanced vaccine accessibility nationwide by enabling community pharmacies to administer free NIP vaccines to eligible individuals aged five and over, supported by payments of AUD 18.85 per vaccination.

• June 2025: Australian Government unveiled the National Immunization Strategy 2025-2030, focusing on increasing immunization uptake, especially within Aboriginal and Torres Strait Islander communities, strengthening trust in vaccines, and enhancing equitable access and immunization data systems.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask an Analyst for Your Customized Sample Report: https://www.imarcgroup.com/request?type=report&id=32305&flag=C

Contact Us

IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201-971-6302

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.